Lakefront Biotherapeutics (LKFT) EBT Margin (2014 - 2026)
Lakefront Biotherapeutics (LKFT) posted quarterly EBT Margin of 215.34% for Q1 2026, up 42389.0% year-on-year from N/an in Q1 2025, and up 147.69% on a QoQ basis from 86.94% in Q4 2025.
Lakefront Biotherapeutics (LKFT) EBT Margin (2014 - 2026) Analysis & Trends
Lakefront Biotherapeutics (LKFT) has reported EBT Margin for 13 consecutive years, with 215.34% the latest figure, recorded in Q1 2026.
- Quarterly EBT Margin rose 42389.0% year-over-year to 215.34% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 45.14% (up 12649.0% YoY) and the FY2025 annual result came in at 27.05%, up 2817.0% from the prior year.
- EBT Margin rose to 215.34% in Q1 2026 per LKFT's latest filing, from 86.94% in the prior quarter.
- Over the last five years, EBT Margin for LKFT reached as high as 240.09% in Q2 2025 and fell as low as 678.28% in Q3 2025.
- A 5-year average of 59.88% and a median of 35.02% in 2022 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2022 — EBT Margin soared 273065 bps — and 2025, when it plunged 62891 bps.
- Year by year, EBT Margin stood at 35.02% in 2022, then fell by 9 bps to 38.07% in 2023, then surged by 535 bps to 165.49% in 2024, then plunged by 47 bps to 86.94% in 2025, then soared by 148 bps to 215.34% in 2026.
- According to Business Quant data, EBT Margin over the past three periods registered 215.34%, 86.94%, and 678.28% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 17.13% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 34.77% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Lakefront Biotherapeutics | 1.85 Bn | -1.64 Bn | 1.91 Mn | 215.34% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 215.34% |
| Dec 31, 2025 | 86.94% |
| Sep 30, 2025 | -678.28% |
| Jun 30, 2025 | 240.09% |
| Mar 31, 2025 | -208.55% |
| Dec 31, 2024 | 165.49% |
| Sep 30, 2024 | -49.37% |
| Jun 30, 2024 | -94.21% |
| Mar 31, 2024 | 36.74% |
| Dec 31, 2023 | -38.07% |
| Sep 30, 2023 | -23.23% |
| Jun 30, 2023 | -22.49% |
| Mar 31, 2023 | -19.43% |
| Dec 31, 2022 | -35.02% |
| Sep 30, 2022 | -149.68% |
| Jun 30, 2022 | -363.78% |
| Mar 31, 2022 | -80.40% |
| Dec 31, 2021 | 1.81% |
| Sep 30, 2021 | -2,880.33% |
| Jun 30, 2021 | -46.47% |